A detailed history of Wells Fargo & Company transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 22,210 shares of GLUE stock, worth $188,562. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,210
Previous 16,308 36.19%
Holding current value
$188,562
Previous $60,000 95.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.59 - $6.97 $21,188 - $41,136
5,902 Added 36.19%
22,210 $117,000
Q2 2024

Aug 13, 2024

BUY
$3.38 - $7.86 $10,440 - $24,279
3,089 Added 23.37%
16,308 $60,000
Q1 2024

May 10, 2024

BUY
$4.26 - $8.46 $5,691 - $11,302
1,336 Added 11.24%
13,219 $93,000
Q4 2023

Feb 09, 2024

BUY
$2.5 - $5.93 $5,317 - $12,613
2,127 Added 21.8%
11,883 $67,000
Q3 2023

Nov 13, 2023

SELL
$4.78 - $7.22 $18,613 - $28,114
-3,894 Reduced 28.53%
9,756 $46,000
Q2 2023

Aug 15, 2023

BUY
$4.53 - $8.4 $36,842 - $68,317
8,133 Added 147.42%
13,650 $93,000
Q1 2023

May 12, 2023

BUY
$5.95 - $8.21 $32,826 - $45,294
5,517 New
5,517 $42,000
Q3 2022

Nov 14, 2022

SELL
$7.17 - $12.16 $1,240 - $2,103
-173 Reduced 68.38%
80 $1,000
Q2 2022

Aug 12, 2022

SELL
$6.15 - $14.99 $95,269 - $232,210
-15,491 Reduced 98.39%
253 $2,000
Q1 2022

May 16, 2022

SELL
$10.36 - $20.41 $372 - $734
-36 Reduced 0.23%
15,744 $221,000
Q4 2021

Feb 14, 2022

BUY
$16.28 - $27.15 $255,970 - $426,879
15,723 Added 27584.21%
15,780 $322,000
Q3 2021

Nov 15, 2021

BUY
$18.59 - $42.21 $1,059 - $2,405
57 New
57 $1,000

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $397M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.